<?xml version="1.0" encoding="UTF-8"?>
<!-- generated by CLiX/Wiki2XML [MPI-Inf, MMCI@UdS] $LastChangedRevision: 92 $ on 16.04.2009 22:15:03[mciao0826] -->
<!DOCTYPE article SYSTEM "../article.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink">
<entity  confidence="0.9511911446218017" wordnetid="100001740">
<header>
<title>Treatment of Crohn&apos;s disease</title>
<id>6180485</id>
<revision>
<id>240610485</id>
<timestamp>2008-09-24T04:22:56Z</timestamp>
<contributor>
<username>Diberri</username>
<id>35331</id>
</contributor>
</revision>
<categories>
<category>Digestive diseases</category>
<category>Autoimmune diseases</category>
<category>Genetic disorders</category>
<category>Gastroenterology</category>
</categories>
</header>
<bdy>

<b>Treatment of <link xlink:type="simple" xlink:href="../522/63522.xml">
Crohn's disease</link></b> involves first treating the <link xlink:type="simple" xlink:href="../539/16453539.xml">
acute</link> symptoms of the disease, then maintaining <link xlink:type="simple" xlink:href="../094/5827094.xml">
remission</link>. Treatment initially involves the use of <link xlink:type="simple" xlink:href="../121/180121.xml">
medication</link>s to eliminate <link xlink:type="simple" xlink:href="../220/37220.xml">
infection</link>s, generally  <link xlink:type="simple" xlink:href="../805/1805.xml">
antibiotic</link>s, and reduce <link xlink:type="simple" xlink:href="../425/70425.xml">
inflammation</link>, generally <link xlink:type="simple" xlink:href="../981/2715981.xml">
aminosalicylate</link> anti-inflammatory drugs and <link xlink:type="simple" xlink:href="../996/57996.xml">
corticosteroid</link>s. <link xlink:type="simple" xlink:href="../599/45599.xml">
Surgery</link> may be required for complications such as obstructions or abscesses, or if the disease does not respond to drugs within a reasonable time.<p>

Once remission is induced, the goal of treatment becomes maintenance of remission, avoiding the return of active disease, or "flares". Because of side-effects, the prolonged use of corticosteroids is avoided. Although some people are able to maintain remission with aminosalicylates alone, many require immunosuppressive drugs.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%221%22])">1</ref></p>

<sec>
<st>
Aminosalicylate anti-inflammatory drugs</st>

<p>

5-aminosalicylates (5-ASA) include the following:
<list>
<entry level="1" type="bullet">

<link xlink:type="simple" xlink:href="../052/1111052.xml">
Mesalazine</link> or mesalamine, which is marketed in the forms Asacol, Pentasa, Salofalk, Dipentum and Rowasa.</entry>
<entry level="1" type="bullet">

<link xlink:type="simple" xlink:href="../360/1224360.xml">
Sulfasalazine</link>, which is converted to 5-ASA and sulfapyridine by intestinal bacteria. The sulfapyridine may have some therapeutic effect in rheumatoid arthritis. However, the sulfapyridine component is often the limiting factor in treatment of Crohn's disease because of high side-effect profile.</entry>
</list>

5-ASA compounds have been shown to be useful in the treatment of mild-to-moderate Crohn's disease.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%222%22])">2</ref>  They are usually considered to be first line therapy for disease in the <link xlink:type="simple" xlink:href="../599/99599.xml">
ileum</link> and right side of the colon particularly due to their lower side effect profile compared to corticosteroids.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%223%22])">3</ref></p>

</sec>
<sec>
<st>
Corticosteroid anti-inflammatory drugs</st>
<p>

<image location="left" width="100px" src="Cortifoam.jpg" type="thumb">
<caption>

Steroid <link xlink:type="simple" xlink:href="../877/83877.xml">
enema</link>s can be used for treatment of rectal disease symptoms
</caption>
</image>
</p>
<p>

<b><link xlink:type="simple" xlink:href="../996/57996.xml">
Corticosteroid</link>s</b> are a class of anti-inflammatory drug that are used primarily for treatment of moderate to severe flares of Crohn's disease.  They are used more sparingly due to the availability of effective treatments with less side-effects.  The side effects of corticosteroids include <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../373/92373.xml">
Cushing's syndrome</link></disease>
, <link xlink:type="simple" xlink:href="../419/20419.xml">
mania</link>, <link xlink:type="simple" xlink:href="../798/50798.xml">
insomnia</link>, <link xlink:type="simple" xlink:href="../432/77432.xml">
hypertension</link>, high blood <link xlink:type="simple" xlink:href="../950/12950.xml">
glucose</link>, <link xlink:type="simple" xlink:href="../461/22461.xml">
osteoporosis</link>, and <link xlink:type="simple" xlink:href="../676/1498676.xml">
avascular necrosis</link> of long bones. These should not be confused with the <link xlink:type="simple" xlink:href="../324/19218324.xml">
anabolic steroid</link>s used to enhance athletic performance.</p>
<p>

The most commonly prescribed oral steroid is <link xlink:type="simple" xlink:href="../515/530515.xml">
prednisone</link>, which is typically dosed at 0.5 mg/kg for induction of remission.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%224%22])">4</ref>  Intravenous steroids are used for cases refractory to oral steroids, or where oral steroids cannot be taken.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%225%22])">5</ref>  These are administered in the hospital setting.  Because corticosteroids reduce the ability to fight <link xlink:type="simple" xlink:href="../220/37220.xml">
infection</link>, care must be used to ensure that there isn't an active infection, particularly an intra-abdominal <link xlink:type="simple" xlink:href="../032/1032.xml">
abscess</link> before the initiation of steroids.</p>
<p>

<link xlink:type="simple" xlink:href="../814/1264814.xml">
Budesonide</link> is an oral corticosteroid with limited absorption and high level of first-pass <link xlink:type="simple" xlink:href="../374/20374.xml">
metabolism</link>, meaning that less quantities of steroid enter into the bloodstream.  It has been shown to be useful in the treatment of mild-to-moderate Crohn's disease<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%226%22])">6</ref> and for maintenance of remission in Crohn's disease.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%227%22])">7</ref>  Formulated as Entocort, budesonide is released in the <link xlink:type="simple" xlink:href="../599/99599.xml">
ileum</link> and right colon, and is therefore has a topical effect against disease in that area.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%226%22])">6</ref></p>
<p>

<link xlink:type="simple" xlink:href="../814/1264814.xml">
Budesonide</link> is also useful when used in combination with <link xlink:type="simple" xlink:href="../805/1805.xml">
antibiotic</link>s for active Crohn's disease.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%228%22])">8</ref></p>
<p>

Steroid enemas can also be used for disease of the lower colon and <link xlink:type="simple" xlink:href="../671/19385671.xml">
rectum</link>, in order to treat symptoms.  <link xlink:type="simple" xlink:href="../380/335380.xml">
Hydrocortisone</link> and budesonide liquid and foam enemas are being marketed for these reasons.</p>
<p>

<link xlink:type="simple" xlink:href="../996/57996.xml">
Corticosteroid</link>s however have a host of side effects, some very serious, and it is desirable to curtail their use whenever possible.</p>

</sec>
<sec>
<st>
Mercaptopurine immunosuppressing drugs</st>
<p>

<image location="right" width="150px" src="Imuran_2.JPG" type="thumb">
</image>
</p>
<p>

<link xlink:type="simple" xlink:href="../543/504543.xml">
Azathioprine</link> and <link xlink:type="simple" xlink:href="../306/1814306.xml">
6-mercaptopurine</link> (6-MP) are the most used immunosuppressants for maintenance therapy of Crohn's disease.  They are <link xlink:type="simple" xlink:href="../652/23652.xml">
purine</link> anti-metabolites, meaning that they interfere with the synthesis of purines required for <link xlink:type="simple" xlink:href="../480/144480.xml">
inflammatory cells</link>.  They have a duration of action of months, making it unwieldy to use them for induction of remission.  Both drugs are dosed at 1.5 to 2.5 mg/kg, with literature supporting the use of higher doses.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%229%22])">9</ref></p>
<p>

Azathioprine and 6-MP have been found to be useful for the following indications:
<list>
<entry level="1" type="bullet">

For maintenance therapy for people who are dependent on steroids.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2210%22])">10</ref></entry>
<entry level="1" type="bullet">

Fistulizing disease.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2211%22])">11</ref></entry>
<entry level="1" type="bullet">

Induction of remission in steroid refractory disease.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2212%22])">12</ref></entry>
<entry level="1" type="bullet">

Maintenance of remission after surgery for Crohn's disease.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2213%22])">13</ref></entry>
</list>
</p>
<p>

<link xlink:type="simple" xlink:href="../543/504543.xml">
Azathioprine</link> is however a particularily dangerous drug, with great potential for inviting a host of potentially fatal infections, and is also listed by the FDA as a human <link xlink:type="simple" xlink:href="../445/6445.xml">
carcinogen</link>.</p>

</sec>
<sec>
<st>
Infliximab</st>

<p>

<substance wordnetid="100020090" confidence="0.8">
<substance wordnetid="100019613" confidence="0.8">
<compound wordnetid="114818238" confidence="0.8">
<protein wordnetid="114728724" confidence="0.8">
<macromolecule wordnetid="114944888" confidence="0.8">
<chemical wordnetid="114806838" confidence="0.8">
<part wordnetid="113809207" confidence="0.8">
<organic_compound wordnetid="114727670" confidence="0.8">
<molecule wordnetid="114682133" confidence="0.8">
<inhibitor wordnetid="114724436" confidence="0.8">
<material wordnetid="114580897" confidence="0.8">
<link xlink:type="simple" xlink:href="../466/324466.xml">
Infliximab</link></material>
</inhibitor>
</molecule>
</organic_compound>
</part>
</chemical>
</macromolecule>
</protein>
</compound>
</substance>
</substance>
, marketed as <b>Remicade</b>, is a mouse-human <link xlink:type="simple" xlink:href="../398/9652398.xml">
chimeric antibody</link> that targets <link xlink:type="simple" xlink:href="../736/9913736.xml">
tumour necrosis factor</link>, a <link xlink:type="simple" xlink:href="../663/153663.xml">
cytokine</link> in the inflammatory response.  It is administered intravenously and dosed per weight.</p>
<p>

Infliximab has found utility as follows:
<list>
<entry level="1" type="bullet">

Maintenance of remission for people with Crohn's disease.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2214%22])">14</ref></entry>
<entry level="1" type="bullet">

Induction of remission for people with Crohn's disease.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2214%22])">14</ref></entry>
<entry level="1" type="bullet">

Maintenance for fistulizing Crohn's disease.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2215%22])">15</ref></entry>
</list>
</p>
<p>

Side effects of <link xlink:type="simple" xlink:href="../466/324466.xml">
infliximab</link>, like other <link xlink:type="simple" xlink:href="../940/168940.xml">
immunosuppressant</link>s of the <link xlink:type="simple" xlink:href="../108/291108.xml">
TNF</link> class, can be serious and potentially fatal, and <link xlink:type="simple" xlink:href="../466/324466.xml">
infliximab</link> carries an FDA <link xlink:type="simple" xlink:href="../050/18950050.xml">
black-box</link> warning on the label. Listed side effects include <link xlink:type="simple" xlink:href="../058/335058.xml">
hypersensitivity</link> and <link xlink:type="simple" xlink:href="../313/55313.xml">
allergic</link> reactions, risk of re-activation of <link xlink:type="simple" xlink:href="../653/30653.xml">
tuberculosis</link>, <link xlink:type="simple" xlink:href="../772/12800772.xml">
serum sickness</link>, and risk of <link xlink:type="simple" xlink:href="../603/50603.xml">
multiple sclerosis</link>.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2216%22])">16</ref> Serious side effect also include <link xlink:type="simple" xlink:href="../422/71422.xml">
lymphoma</link> and severe <link xlink:type="simple" xlink:href="../220/37220.xml">
infections</link>, inclduing <link xlink:type="simple" xlink:href="../160/25160.xml">
progressive multifocal leukoencephalopathy</link> (PML) an opportunistic viral infection of the brain that can cause death.</p>

</sec>
<sec>
<st>
Adalimumab</st>

<p>

<substance wordnetid="100020090" confidence="0.8">
<inhibitor wordnetid="114724436" confidence="0.8">
<link xlink:type="simple" xlink:href="../708/1829708.xml">
Adalimumab</link></inhibitor>
</substance>
, marketed as <b>Humira</b>, like infliximab is an antibody that targets <link xlink:type="simple" xlink:href="../736/9913736.xml">
tumour necrosis factor</link>.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2217%22])">17</ref>
Adalimumab has been shown to reduce the signs and symptoms of, and is approved for treatment of, moderate to severe <link>
Crohn’s disease</link> (CD) in adults who have not responded well to conventional treatments and who have lost response to, or are unable to tolerate <link xlink:type="simple" xlink:href="../466/324466.xml">
infliximab</link>.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2218%22])">18</ref></p>
<p>

<substance wordnetid="100020090" confidence="0.8">
<inhibitor wordnetid="114724436" confidence="0.8">
<link xlink:type="simple" xlink:href="../708/1829708.xml">
Adalimumab</link></inhibitor>
</substance>
 also has a number of serious, potentially fatal, safety concerns characteristic of the anti-TNFα drugs. It too has a <link xlink:type="simple" xlink:href="../050/18950050.xml">
black-box</link> warning on its FDA label. Listed potential side effects include serious and sometimes fatal blood disorders; serious <link xlink:type="simple" xlink:href="../220/37220.xml">
infection</link>s including include TB (<link xlink:type="simple" xlink:href="../653/30653.xml">
tuberculosis</link>) and infections caused by viruses, fungi, or bacteria; rare reports of <link xlink:type="simple" xlink:href="../422/71422.xml">
lymphoma</link> and solid tissue <link xlink:type="simple" xlink:href="../219/105219.xml">
cancer</link>s; rare reports of serious <link xlink:type="simple" xlink:href="../301/17384301.xml">
liver</link> injury; and rare reports of <link xlink:type="simple" xlink:href="../319/19319.xml">
demyelinating</link> <link xlink:type="simple" xlink:href="../251/7251.xml">
central nervous system</link> disorders); and rare reports of cardiac failure.</p>

</sec>
<sec>
<st>
Natalizumab</st>

<p>

<physical_entity wordnetid="100001930" confidence="0.8">
<causal_agent wordnetid="100007347" confidence="0.8">
<agent wordnetid="109190918" confidence="0.8">
<link xlink:type="simple" xlink:href="../482/1979482.xml">
Natalizumab</link></agent>
</causal_agent>
</physical_entity>
, marketed as <b>Tysabri</b>, is an anti-<link xlink:type="simple" xlink:href="../302/15302.xml">
integrin</link> monoclonal antibody that has shown utility as induction and maintenance treatment for moderate to severe Crohn's disease.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2219%22])">19</ref> <physical_entity wordnetid="100001930" confidence="0.8">
<causal_agent wordnetid="100007347" confidence="0.8">
<agent wordnetid="109190918" confidence="0.8">
<link xlink:type="simple" xlink:href="../482/1979482.xml">
Natalizumab</link></agent>
</causal_agent>
</physical_entity>
 may be appropriate in patients who do not respond to medications that block <link xlink:type="simple" xlink:href="../843/240843.xml">
tumor necrosis factor-alpha</link> such as <link xlink:type="simple" xlink:href="../466/324466.xml">
infliximab</link>.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2220%22])">20</ref>  </p>
<p>

In January 2008, the FDA approved natalizumab for both induction of remission and maintenance of remission for moderate to severe Crohn's disease.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2221%22])">21</ref></p>
<p>

A total of 3 large <link xlink:type="simple" xlink:href="../180/163180.xml">
randomized controlled trial</link>s have demonstrated that natalizumab is effective in increasing rates of <link xlink:type="simple" xlink:href="../094/5827094.xml">
remission</link><ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2222%22])">22</ref> and maintaining symptom-free status<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2223%22])">23</ref> in patients with Crohn's disease. </p>
<p>

Like infliximab, natalizumab has also been linked to PML (though only when used in combination with <link xlink:type="simple" xlink:href="../139/382139.xml">
interferon beta-1a</link>).<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2224%22])">24</ref><ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2225%22])">25</ref>  The label also recommends monitoring of liver enzymes due to conerns over possible damage or failure.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2226%22])">26</ref></p>

</sec>
<sec>
<st>
 Surgery </st>
<p>

Surgery is normally reserved for complications of Crohn's disease or when disease that resists treatment with drugs is confined to one location that can be removed.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2227%22])">27</ref> Surgery is often used to manage complications of Crohn's disease, including <link xlink:type="simple" xlink:href="../559/210559.xml">
fistula</link>e, small <link xlink:type="simple" xlink:href="../424/324424.xml">
bowel obstruction</link>, <link xlink:type="simple" xlink:href="../979/206979.xml">
colon cancer</link>, <link xlink:type="simple" xlink:href="../931/4472931.xml">
small intestine cancer</link> and fibrostenotic <link xlink:type="simple" xlink:href="../707/2905707.xml">
stricture</link>s, when <link xlink:type="simple" xlink:href="../845/10471845.xml">
strictureplasty</link> (expansion of the stricture) is sometimes performed. Otherwise, and for other complications, <link xlink:type="simple" xlink:href="../018/2244018.xml#xpointer(//*[./st=%22Surgery%22])">
resection</link> and anastomosis - the removal of the affected section of intestine and the rejoining of the healthy sections - is the surgery usually performed for Crohn's disease (e.g., <link xlink:type="simple" xlink:href="../708/1883708.xml">
ileocolonic resection</link>). Neither type of surgery cures Crohn's disease, as recurrence often reappears in previously unaffected areas of the intestine.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2228%22])">28</ref></p>
<p>

Small intestine <link xlink:type="simple" xlink:href="../166/167166.xml">
transplants</link> are experimental as of yet, and are usually only done when there is a risk of <link xlink:type="simple" xlink:href="../053/1257053.xml">
short bowel syndrome</link> due to repeated resection surgeries.</p>

</sec>
<sec>
<st>
 Diet and lifestyle </st>
<p>

There is no evidence that <link xlink:type="simple" xlink:href="../924/639924.xml">
diet</link> causes or cures Crohn's disease. If a person with Crohn's finds that certain foods increase or decrease the symptoms, then they may adjust their diet accordingly. A food diary is recommended to see what positive or negative effects particular foods have <weblink xlink:type="simple" xlink:href="http://www.ccfa.org">
http://www.ccfa.org</weblink>. </p>
<p>

<link xlink:type="simple" xlink:href="../306/999306.xml">
Fish oil</link> has been found to be effective in reducing the chance of relapse in less severe cases.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2229%22])">29</ref>  People with <link xlink:type="simple" xlink:href="../873/56873.xml">
lactose intolerance</link> due to small bowel disease may benefit from avoiding <link xlink:type="simple" xlink:href="../643/18643.xml">
lactose</link>-containing foods.  Many diets, for instance, <link xlink:type="simple" xlink:href="../815/5296815.xml">
Specific Carbohydrate Diet</link>, have been proposed for treatment of Crohn's disease, and many do improve symptoms, but none have been proven to actually cure Crohn's disease.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2230%22])">30</ref>  This diet though usually needs adjustments for patients so that they can handle the diet. A <link xlink:type="simple" xlink:href="../031/3012031.xml">
low residue diet</link> may be used to reduce the volume of stools excreted daily.  Patients who cannot eat are recommended to take total parenteral nutrition (TPN) - a source of vitamins and nutrients.<weblink xlink:type="simple" xlink:href="http://hopkins-gi.nts.jhu.edu/pages/latin/templates/index.cfm?pg=disease2&amp;organ=6&amp;disease=21&amp;lang_id=1">
http://hopkins-gi.nts.jhu.edu/pages/latin/templates/index.cfm?pg=disease2&amp;organ=6&amp;disease=21&amp;lang_id=1</weblink>  <link xlink:type="simple" xlink:href="../072/146072.xml">
Stress</link> is not proven to aggravate or induce the symptoms of Crohn’s disease.<weblink xlink:type="simple" xlink:href="http://www.ccfa.org/printview?pageUrl=/info/about/crohns">
http://www.ccfa.org/printview?pageUrl=/info/about/crohns</weblink> If sufferers observe that <link xlink:type="simple" xlink:href="../475/255475.xml">
Stress Management</link> is a successful method of suppressing the illness in their bodies, then they may manage stress as they see fit.  Conversely, stress is likely to be caused by the flaring up of the disease and this would make day to day life more difficult.
Smoking has also been noted to have an association with Crohn's, and smokers with Crohn's are encouraged to quit.</p>
<p>

Because the terminal ileum is the most common site of involvement and is the site for <link xlink:type="simple" xlink:href="../634/14538634.xml">
vitamin B12</link> absorption, people with Crohn's disease are at risk for B12 deficiency and may need supplementation.  In cases with extensive small intestine involvement, the fat soluble vitamins <link xlink:type="simple" xlink:href="../115/54115.xml">
A</link>, <link xlink:type="simple" xlink:href="../106/54106.xml">
D</link>, <link xlink:type="simple" xlink:href="../105/54105.xml">
E</link> and <link xlink:type="simple" xlink:href="../103/54103.xml">
K</link> can be deficient. <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../286/5573286.xml">
Folate deficiency</link></disease>
 is a risk when being treated with methotrexate.</p>

</sec>
<sec>
<st>
Helminthic therapy</st>
<p>

In an experimental idea called <computer wordnetid="103082979" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../331/2846331.xml">
Helminthic therapy</link></computer>
, moderate <link xlink:type="simple" xlink:href="../203/1079203.xml">
hookworm</link> infections have been demonstrated to have beneficial effects on hosts suffering from diseases linked to overactive immune systems.  This is possibly explained by the <link xlink:type="simple" xlink:href="../814/407814.xml">
hygiene hypothesis</link>. Helminthic therapy may help sufferers of <link xlink:type="simple" xlink:href="../522/63522.xml">
Crohn's Disease</link><ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2231%22])">31</ref> Hookworm therapy is currently in the trial stage at the <university wordnetid="108286163" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../631/96631.xml">
University of Nottingham</link></university>
.  Due to the unconventional nature of this therapy, it is not widely used.</p>

</sec>
<sec>
<st>
 Complementary and alternative medicine </st>
<p>

More than half of Crohn's disease sufferers have tried complementary or alternative therapy.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2232%22])">32</ref> These include diets, <link xlink:type="simple" xlink:href="../740/731740.xml">
probiotics</link>, fish oil and other <work wordnetid="100575741" confidence="0.8">
<treatment wordnetid="100658082" confidence="0.8">
<event wordnetid="100029378" confidence="0.8">
<care wordnetid="100654885" confidence="0.8">
<medical_care wordnetid="100657604" confidence="0.8">
<act wordnetid="100030358" confidence="0.8">
<therapy wordnetid="100661091" confidence="0.8">
<psychological_feature wordnetid="100023100" confidence="0.8">
<activity wordnetid="100407535" confidence="0.8">
<link xlink:type="simple" xlink:href="../973/439973.xml">
herbal</link></activity>
</psychological_feature>
</therapy>
</act>
</medical_care>
</care>
</event>
</treatment>
</work>
 and nutritional supplements. The benefit of these medications is uncertain.</p>

<ss1>
<st>
Acupuncture</st>
<p>

<link xlink:type="simple" xlink:href="../537/1537.xml">
Acupuncture</link> is used to treat inflammatory bowel disease in <link xlink:type="simple" xlink:href="../862/5042862.xml">
China</link>, and is being used more frequently in <link xlink:type="simple" xlink:href="../831/74831.xml">
Western society</link>.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2233%22])">33</ref>  There is evidence that acupuncture has benefits beyond the <link>
placebo effect</link>, improving quality of life, general well-being and a small decrease in blood-bound inflammatory markers.</p>

</ss1>
</sec>
<sec>
<st>
Other medications</st>
<p>

<list>
<entry level="1" type="bullet">

<link xlink:type="simple" xlink:href="../517/286517.xml">
Methotrexate</link> is a <link xlink:type="simple" xlink:href="../117/54117.xml">
folate</link> anti-metabolite drug which is also used for <link xlink:type="simple" xlink:href="../172/7172.xml">
chemotherapy</link>.  It is useful in maintenance of remission for those no longer taking corticosteroids.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2234%22])">34</ref></entry>
<entry level="1" type="bullet">

<physical_entity wordnetid="100001930" confidence="0.8">
<substance wordnetid="100020090" confidence="0.8">
<causal_agent wordnetid="100007347" confidence="0.8">
<antibiotic wordnetid="102716866" confidence="0.8">
<antibacterial wordnetid="102716205" confidence="0.8">
<medicine wordnetid="103740161" confidence="0.8">
<agent wordnetid="114778436" confidence="0.8">
<agent wordnetid="109190918" confidence="0.8">
<drug wordnetid="103247620" confidence="0.8">
<link xlink:type="simple" xlink:href="../139/315139.xml">
Metronidazole</link></drug>
</agent>
</agent>
</medicine>
</antibacterial>
</antibiotic>
</causal_agent>
</substance>
</physical_entity>
 and <link xlink:type="simple" xlink:href="../773/6773.xml">
ciprofloxacin</link> are antibiotics which are used to treat Crohn's that have colonic or perianal involvement, although this use has not been approved by the <link xlink:type="simple" xlink:href="../632/11632.xml">
Food and Drug Administration</link>.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2235%22])">35</ref>  They are also used for treatment of complications, including abscesses and other infections accompanying Crohn's disease.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%225%22])">5</ref></entry>
<entry level="1" type="bullet">

<link xlink:type="simple" xlink:href="../078/51078.xml">
Thalidomide</link> has shown response in reversing <link xlink:type="simple" xlink:href="../002/197002.xml">
endoscopic</link> evidence of disease.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2236%22])">36</ref></entry>
<entry level="1" type="bullet">

<link xlink:type="simple" xlink:href="../440/175440.xml">
Cannabis</link> may also be used to treat Crohn's Disease with its anti-inflammatory properties.  Cannabis and cannabis-derived drugs may also help to heal the gut lining.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2237%22])">37</ref></entry>
</list>
</p>

</sec>
<sec>
<st>
 Research on medications in progress </st>
<p>

<image location="right" width="200px" src="Trichuris_egg.jpg" type="thumb">
<caption>

Egg of <it>Trichuris spp.</it> <link xlink:type="simple" xlink:href="../211/60211.xml">
whipworm</link>.  <it>Trichuris suis</it> or pig whipworm has been investigated for treatment of Crohn's disease.
</caption>
</image>
</p>
<p>

Many <link xlink:type="simple" xlink:href="../717/241717.xml">
clinical trials</link> have been recently completed or are ongoing for new therapies for Crohn's disease.  They include the following:
<list>
<entry level="1" type="bullet">

<link xlink:type="simple" xlink:href="../441/6352441.xml">
Certolizumab</link> is a <link xlink:type="simple" xlink:href="../203/147203.xml">
PEGylated</link> <link xlink:type="simple" xlink:href="../ury/24th_century.xml">
Fab</link> fragment of a humanized anti-<link xlink:type="simple" xlink:href="../108/291108.xml">
TNF alpha</link> <link xlink:type="simple" xlink:href="../043/315043.xml">
monoclonal antibody</link> that was found to have efficacy over <link xlink:type="simple" xlink:href="../821/142821.xml">
placebo</link> in one large trial.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2238%22])">38</ref></entry>
<entry level="1" type="bullet">

<it>ABT-874</it> is a human anti-<link xlink:type="simple" xlink:href="../972/1941972.xml">
IL-12</link> <link xlink:type="simple" xlink:href="../043/315043.xml">
monoclonal antibody</link> being developed by <company wordnetid="108058098" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../730/488730.xml">
Abbott Laboratories</link></company>
 in conjunction with Cambridge Antibody Technology for the treatment of multiple autoimmune diseases including Crohn's disease. Phase II trials have been completed and showed promising results,<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2239%22])">39</ref></entry>
<entry level="1" type="bullet">

<link xlink:type="simple" xlink:href="../774/5286774.xml">
Sargramostim</link>, or granulocyte-monocyte colony stimulating factor (GM-CSF) has been shown to substabtially improve health-related quality of life in pilot studies, measured by an increase in score of a 32-item IBD questionnaire. <ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2240%22])">40</ref> A recent Phase II trial showed that Sargramostim significantly decreased CD severity (48% compared to 26% placebo group) and improved quality of life (40% versus 19% for placebo).<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2241%22])">41</ref></entry>
<entry level="1" type="bullet">

<it><condition wordnetid="113920835" confidence="0.8">
<state wordnetid="100024720" confidence="0.8">
<link xlink:type="simple" xlink:href="../211/60211.xml">
Trichuris suis</link></state>
</condition>
</it> is a pig whipworm that been shown in one study to improve Crohn's disease symptoms.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2242%22])">42</ref></entry>
<entry level="1" type="bullet">

Autologous  <link xlink:type="simple" xlink:href="../810/575810.xml">
stem cell transplant</link>s have also been evaluated.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2243%22])">43</ref></entry>
<entry level="1" type="bullet">

Rifabutin, clarithromycin and clofazimine are antibiotics designed to attack <link xlink:type="simple" xlink:href="../698/988698.xml">
mycobacterium avium subsp. paratuberculosis</link>, which may be a cause of Chron's disease. This treatment, called Myoconda, is being tested by <company wordnetid="108058098" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../316/5709316.xml">
Giaconda</link></company>
.</entry>
</list>
</p>

</sec>
<sec>
<st>
 References </st>

<p>

<reflist>
<entry id="1">
 <cite style="font-style:normal">Hanauer SB, Sandborn W&#32;(2001).&#32;"<weblink xlink:type="simple" xlink:href="http://www.ibdforum.com/proto/acghanauer.pdf">
Management of Crohn's disease in adults</weblink>"&#32;(pdf). <it>Am. J. Gastroenterol.</it>&#32;<b>96</b>&#32;(3): 635–43. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.1111%2Fj.1572-0241.2001.03671.x">
10.1111/j.1572-0241.2001.03671.x</weblink>. PMID 11280528. Retrieved on <link>
2008-02-15</link>.</cite>&nbsp;</entry>
<entry id="2">
 <cite style="font-style:normal">Hanauer SB, Strömberg U&#32;(2004).&#32;"Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials". <it>Clin. Gastroenterol. Hepatol.</it>&#32;<b>2</b>&#32;(5): 379–88. PMID 15118975.</cite>&nbsp;</entry>
<entry id="3">
 <cite style="font-style:normal">Prantera C, Cottone M, Pallone F, et al&#32;(1999).&#32;"Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial". <it>Gastroenterology</it>&#32;<b>116</b>&#32;(3): 521–6. PMID 10029609.</cite>&nbsp;.</entry>
<entry id="4">
 <cite style="font-style:normal">Hanauer SB&#32;(1991).&#32;"Sulfasalazine vs. steroids in Crohn's disease: David vs. Goliath?". <it>Gastroenterology</it>&#32;<b>101</b>&#32;(4): 1130–1. PMID 1679735.</cite>&nbsp;</entry>
<entry id="5">
Gopal, Latha;&#32;Senthil Nachimuthu&#32;(<link>
2006-05-23</link>).&#32;"<weblink xlink:type="simple" xlink:href="http://www.emedicine.com/MED/topic477.htm">
Crohn Disease</weblink>".&#32;  eMedicine.&#32;Retrieved on <link>
2006-07-02</link>.</entry>
<entry id="6">
 <cite style="font-style:normal">Greenberg GR, Feagan BG, Martin F, et al&#32;(1994).&#32;"Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group". <it>N. Engl. J. Med.</it>&#32;<b>331</b>&#32;(13): 836–41. PMID 8078529.</cite>&nbsp;</entry>
<entry id="7">
 <cite style="font-style:normal">Sandborn WJ, Löfberg R, Feagan BG, Hanauer SB, Campieri M, Greenberg GR&#32;(2005).&#32;"Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials". <it>Am. J. Gastroenterol.</it>&#32;<b>100</b>&#32;(8): 1780–7. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.1111%2Fj.1572-0241.2005.41992.x">
10.1111/j.1572-0241.2005.41992.x</weblink>. PMID 16086715.</cite>&nbsp;</entry>
<entry id="8">
 <cite style="font-style:normal">Steinhart AH, Feagan BG, Wong CJ, et al&#32;(2002).&#32;"Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial". <it>Gastroenterology</it>&#32;<b>123</b>&#32;(1): 33–40. PMID 12105831.</cite>&nbsp;.</entry>
<entry id="9">
 <cite style="font-style:normal">Podolsky, Daniel K.&#32;(August 2002).&#32;"<weblink xlink:type="simple" xlink:href="http://content.nejm.org/cgi/content/extract/347/6/417">
Inflammatory bowel disease</weblink>". <it>New England Journal of Medicine</it>&#32;<b>346</b>&#32;(6): 417–29. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.1056%2FNEJMra020831">
10.1056/NEJMra020831</weblink>. PMID 12167685. Retrieved on <link>
2006-07-02</link>.</cite>&nbsp;</entry>
<entry id="10">
 <cite style="font-style:normal">Rosenberg JL, Levin B, Wall AJ, Kirsner JB&#32;(1975).&#32;"A controlled trial of azathioprine in Crohn's disease". <it>Am J Dig Dis</it>&#32;<b>20</b>&#32;(8): 721–6. PMID 1098449.</cite>&nbsp;</entry>
<entry id="11">
 <cite style="font-style:normal">Dejaco C, Harrer M, Waldhoer T, Miehsler W, Vogelsang H, Reinisch W&#32;(2003).&#32;"Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease". <it>Aliment. Pharmacol. Ther.</it>&#32;<b>18</b>&#32;(11-12): 1113–20. PMID 14653831.</cite>&nbsp;</entry>
<entry id="12">
 <cite style="font-style:normal">Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C&#32;(2000).&#32;"Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease". <it>Cochrane Database Syst Rev</it>&#32;(2): CD000545. PMID 10796557.</cite>&nbsp;</entry>
<entry id="13">
 <cite style="font-style:normal">Hanauer SB, Korelitz BI, Rutgeerts P, et al&#32;(2004).&#32;"Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial". <it>Gastroenterology</it>&#32;<b>127</b>&#32;(3): 723–9. PMID 15362027.</cite>&nbsp;</entry>
<entry id="14">
 <cite style="font-style:normal">Hanauer SB, Feagan BG, Lichtenstein GR, et al&#32;(2002).&#32;"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial". <it>Lancet</it>&#32;<b>359</b>&#32;(9317): 1541–9. PMID 12047962.</cite>&nbsp;</entry>
<entry id="15">
Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ.  Infliximab maintenance therapy for fistulizing Crohn's disease.  N Engl J Med. 2004 Feb 26;350(9):876-85.  PMID 14985485</entry>
<entry id="17">
 <cite style="font-style:normal">Hanauer SB, Sandborn WJ, Rutgeerts P, et al&#32;(2006).&#32;"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial". <it>Gastroenterology</it>&#32;<b>130</b>&#32;(2): 323–33; quiz 591. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.1053%2Fj.gastro.2005.11.030">
10.1053/j.gastro.2005.11.030</weblink>. PMID 16472588.</cite>&nbsp;</entry>
<entry id="16">
 <cite style="font-style:normal">Rutgeerts P, Van Assche G, Vermeire S&#32;(2006).&#32;"Review article: Infliximab therapy for inflammatory bowel disease--seven years on". <it>Aliment. Pharmacol. Ther.</it>&#32;<b>23</b>&#32;(4): 451–63. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.1111%2Fj.1365-2036.2006.02786.x">
10.1111/j.1365-2036.2006.02786.x</weblink>. PMID 16441465.</cite>&nbsp;</entry>
<entry id="19">
 <cite style="font-style:normal">Sandborn WJ, Colombel JF, Enns R, et al&#32;(2005).&#32;"Natalizumab induction and maintenance therapy for Crohn's disease". <it>N. Engl. J. Med.</it>&#32;<b>353</b>&#32;(18): 1912–25. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.1056%2FNEJMoa043335">
10.1056/NEJMoa043335</weblink>. PMID 16267322.</cite>&nbsp;</entry>
<entry id="18">
"<weblink xlink:type="simple" xlink:href="http://www.rxabbott.com/pdf/humira_medguide.pdf">
Medication guide:  Humira</weblink>"&#32;(pdf).&#32;  <company wordnetid="108058098" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../730/488730.xml">
Abbott Laboratories</link></company>
&#32;(2008-02-01).&#32;Retrieved on <link>
2008-03-25</link>. </entry>
<entry id="21">
"<weblink xlink:type="simple" xlink:href="http://www.fda.gov/bbs/topics/NEWS/2008/NEW01775.html">
FDA Approves Tysabri to Treat Moderate-to-Severe Crohn's Disease</weblink>".&#32;  <link xlink:type="simple" xlink:href="../632/11632.xml">
Food and Drug Administration</link>&#32;(2008-01-14).&#32;Retrieved on <link>
2008-03-09</link>.</entry>
<entry id="20">
 <cite style="font-style:normal">Michetti P, Mottet C, Juillerat P, et al&#32;(2007).&#32;"Severe and steroid-resistant Crohn's disease". <it>Digestion</it>&#32;<b>76</b>&#32;(2): 99–108. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.1159%2F000111023">
10.1159/000111023</weblink>. PMID 18239400.</cite>&nbsp;</entry>
<entry id="23">
 <cite style="font-style:normal">Feagan BG, Sandborn WJ, Hass S, Niecko T, White J&#32;(2007).&#32;"Health-related quality of life during natalizumab maintenance therapy for Crohn's disease". <it>Am. J. Gastroenterol.</it>&#32;<b>102</b>&#32;(12): 2737–46. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.1111%2Fj.1572-0241.2007.01508.x">
10.1111/j.1572-0241.2007.01508.x</weblink>. PMID 18042106.</cite>&nbsp;</entry>
<entry id="22">
 <cite style="font-style:normal">Ghosh S, Goldin E, Gordon F, Malchow H, Rask-Madsen J, Rutgeerts P, Vyhnálek P, Zádorová Z, Palmer T, Donoghue S&#32;(2003).&#32;"Natalizumab for active Crohn's disease". <it>N. Engl. J. Med.</it>&#32;<b>348</b>&#32;(1): 24–32. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.1056%2FNEJMoa020732">
10.1056/NEJMoa020732</weblink>. PMID 12510039.</cite>&nbsp;</entry>
<entry id="25">
 <cite style="font-style:normal">Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D&#32;(2005).&#32;"Progressive multifocal leukoencephalopathy in a patient treated with natalizumab". <it>N. Engl. J. Med.</it>&#32;<b>353</b>&#32;(4): 375–81. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.1056%2FNEJMoa051847">
10.1056/NEJMoa051847</weblink>. PMID 15947078.</cite>&nbsp;</entry>
<entry id="24">
 <cite style="font-style:normal">Kleinschmidt-DeMasters BK, Tyler KL&#32;(2005).&#32;"Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis". <it>N. Engl. J. Med.</it>&#32;<b>353</b>&#32;(4): 369–74. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.1056%2FNEJMoa051782">
10.1056/NEJMoa051782</weblink>. PMID 15947079.</cite>&nbsp;</entry>
<entry id="27">
 <cite style="font-style:normal">Hanauer, Stephen B.&#32;(March 1996).&#32;"<weblink xlink:type="simple" xlink:href="http://content.nejm.org/cgi/content/extract/334/13/841">
Inflammatory bowel disease</weblink>". <it>New England Journal of Medicine</it>&#32;<b>334</b>&#32;(13): 841–848. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.1056%2FNEJM199603283341307">
10.1056/NEJM199603283341307</weblink>. PMID 8596552. Retrieved on <link>
2006-11-10</link>.</cite>&nbsp;</entry>
<entry id="26">
"<weblink xlink:type="simple" xlink:href="http://tysabri.com/en_US/tysb/footer/TYSABRI-pi.pdf">
Tysabri product information sheet</weblink>".&#32;Retrieved on <link>
2008-03-13</link>.</entry>
<entry id="29">
 <cite style="font-style:normal">A Belluzzi, C Brignola, M Campieri, A Pera, S Boschi, and M Miglioli&#32;(June 1996).&#32;"<weblink xlink:type="simple" xlink:href="http://content.nejm.org/cgi/content/abstract/334/24/1557?ijkey=6460c4103d06d06d427a2779ed0d755c3a7671cc&amp;keytype2=tf_ipsecsha">
Effect of an Enteric-Coated Fish-Oil Preparation on Relapses in Crohn's Disease</weblink>"&#32;(abstract page). <it>New England Journal of Medicine</it>&#32;<b>334</b>&#32;(24): 1557–60. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.1056%2FNEJM199606133342401">
10.1056/NEJM199606133342401</weblink>.</cite>&nbsp;</entry>
<entry id="28">
"<weblink xlink:type="simple" xlink:href="http://www.ccfa.org/info/surgery/surgerycd">
Surgery for Crohn's Disease</weblink>".&#32;  Crohn's and Colitis Foundation of America&#32;(March 2006).&#32;Retrieved on <link>
2006-06-08</link>.</entry>
<entry id="31">
 <cite style="font-style:normal">Croese, J.; O'Neil, J.; Masson, J.; Cooke, S.; Melrose, W.; Pritchard, D.; Speare, R.&#32;(2006).&#32;"A proof of concept study establishing Necator americanus in Crohn's patients and reservoir donors". <it>British Medical Journal</it>&#32;<b>55</b>&#32;(1): 136. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.1136%2Fgut.2005.079129">
10.1136/gut.2005.079129</weblink>.</cite>&nbsp;; <weblink xlink:type="simple" xlink:href="http://www.dailymail.co.uk/pages/live/articles/technology/technology.html?in_article_id=481875&amp;in_page_id=1965">
lay summary</weblink></entry>
<entry id="30">
 <cite id="Reference-Gottschall-1994" style="font-style:normal" class="book">Gottschall, Elaine&#32;(1994). Breaking the Vicious Cycle: Intestinal Health Through Diet.&#32;Baltimore:&#32;Kirkton Press. ISBN 0-9692768-1-8.</cite>&nbsp;</entry>
<entry id="34">
 <cite style="font-style:normal">Feagan BG, Fedorak RN, Irvine EJ, et al&#32;(2000).&#32;"A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators". <it>N. Engl. J. Med.</it>&#32;<b>342</b>&#32;(22): 1627–32. PMID 10833208.</cite>&nbsp;</entry>
<entry id="35">
 <cite style="font-style:normal">Ursing B, Alm T, Bárány F, et al&#32;(1982).&#32;"A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Result". <it>Gastroenterology</it>&#32;<b>83</b>&#32;(3): 550–62. PMID 6124474.</cite>&nbsp;</entry>
<entry id="32">
 <cite style="font-style:normal">Caprilli R, Gassull M, Escher J et al.&#32;"European evidence based consensus on the diagnosis and management of Crohn's disease: special situations". <it>Gut</it>&#32;<b>55 Suppl 1</b>: i36–58. PMID 16481630.</cite>&nbsp;</entry>
<entry id="33">
 <cite style="font-style:normal">Joos S, Brinkhaus B, Maluche C, et al&#32;(2004).&#32;"Acupuncture and moxibustion in the treatment of active Crohn's disease: a randomized controlled study". <it>Digestion</it>&#32;<b>69</b>&#32;(3): 131–9. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.1159%2F000078151">
10.1159/000078151</weblink>. PMID 15114043.</cite>&nbsp;</entry>
<entry id="38">
 <cite style="font-style:normal">Schreiber S, Rutgeerts P, Fedorak R, Khaliq-Kareemi M, Kamm M, Boivin M, Bernstein C, Staun M, Thomsen O, Innes A&#32;(2005).&#32;"A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease.". <it>Gastroenterology</it>&#32;<b>129</b>&#32;(3): 807–18. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.1053%2Fj.gastro.2005.06.064">
10.1053/j.gastro.2005.06.064</weblink>. PMID 16143120.</cite>&nbsp;</entry>
<entry id="39">
 <cite style="font-style:normal">Mannon PJ, Fuss IJ, Mayer L, et al&#32;(2004).&#32;"Anti-interleukin-12 antibody for active Crohn's disease". <it>N. Engl. J. Med.</it>&#32;<b>351</b>&#32;(20): 2069–79. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.1056%2FNEJMoa033402">
10.1056/NEJMoa033402</weblink>. PMID 15537905.</cite>&nbsp;</entry>
<entry id="36">
 <cite style="font-style:normal">Cohen LB&#32;(2004).&#32;"Re: Disappearance of Crohn's ulcers in the terminal ileum after thalidomide therapy. Can J Gastroenterol 2004; 18(2): 101-104". <it>Can. J. Gastroenterol.</it>&#32;<b>18</b>&#32;(6): 419; author reply 419. PMID 15230268.</cite>&nbsp;</entry>
<entry id="37">
<weblink xlink:type="simple" xlink:href="http://www.medicalnewstoday.com/articles/28584.php">
Cannabis-based drugs could offer new hope for inflammatory bowel disease patients</weblink></entry>
<entry id="42">
 <cite style="font-style:normal">Summers RW, Elliott DE, Urban JF, Thompson R, Weinstock JV&#32;(2005).&#32;"Trichuris suis therapy in Crohn's disease". <it>Gut</it>&#32;<b>54</b>&#32;(1): 87–90. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.1136%2Fgut.2004.041749">
10.1136/gut.2004.041749</weblink>. PMID 15591509.</cite>&nbsp;</entry>
<entry id="43">
 <cite style="font-style:normal">Oyama Y, Craig RM, Traynor AE, et al&#32;(2005).&#32;"Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease". <it>Gastroenterology</it>&#32;<b>128</b>&#32;(3): 552–63. PMID 15765390.</cite>&nbsp;</entry>
<entry id="40">
 <cite style="font-style:normal">Korzenik JR, Dieckgraefe BK, Valentine JF, Hausman DF, Gilbert MJ&#32;(2005).&#32;"Sargramostim for active Crohn's disease". <it>N. Engl. J. Med.</it>&#32;<b>352</b>&#32;(21): 2193–201. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.1056%2FNEJMoa041109">
10.1056/NEJMoa041109</weblink>. PMID 15917384.</cite>&nbsp;</entry>
<entry id="41">
 B. Dieckgraefe&#32;(2006).&#32;"<weblink xlink:type="simple" xlink:href="http://www.touchalimentarydisease.com/articles.cfm?article_id=6363&amp;level=2">
Improving Mucosal Barrier Function - A Novel Therapeutic Strategy for Crohn's Disease</weblink>".</entry>
</reflist>
</p>

<p>

<table style=";" class="navbox" cellspacing="0">
<row>
<col style="padding:2px;">
<table style="width:100%;background:transparent;color:inherit;;" class="nowraplinks collapsible autocollapse " cellspacing="0">
<row>
<header colspan="2" style=";" class="navbox-title">
Topics related to <link xlink:type="simple" xlink:href="../522/63522.xml">
Crohn's disease</link></header>
</row>
<row style="height:2px;">

</row>
<row>
<col style=";;" class="navbox-group">
Main</col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<link xlink:type="simple" xlink:href="../967/616967.xml">
Inflammatory bowel disease</link>&nbsp;·  <link xlink:type="simple" xlink:href="../887/6809887.xml">
Biological therapy for inflammatory bowel disease</link>&nbsp;·  <link xlink:type="simple" xlink:href="../485/6180485.xml">
Treatment of Crohn's disease</link>&nbsp;·  <link xlink:type="simple" xlink:href="../928/7016928.xml">
Crohn's Disease Activity Index</link></col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";;" class="navbox-group">
Related terms</col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<link xlink:type="simple" xlink:href="../703/593703.xml">
Abdominal pain</link>&nbsp;·  <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../885/1560885.xml">
Anal abscess</link></disease>
&nbsp;·  <link xlink:type="simple" xlink:href="../731/2949731.xml">
Erythema nodosum</link>&nbsp;·  <link xlink:type="simple" xlink:href="../559/210559.xml">
Fistula</link>&nbsp;·  <link xlink:type="simple" xlink:href="../252/446252.xml">
Granuloma</link>&nbsp;·  <link xlink:type="simple" xlink:href="../599/99599.xml">
Ileum</link>&nbsp;·  <link xlink:type="simple" xlink:href="../949/513949.xml">
Ileitis</link>&nbsp;·  <link xlink:type="simple" xlink:href="../953/820953.xml">
Malabsorption</link>&nbsp;·  <link xlink:type="simple" xlink:href="../913/2161913.xml">
Proctitis</link>&nbsp;·  <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../712/7023712.xml">
Protein losing enteropathy</link></disease>
&nbsp;·  <link xlink:type="simple" xlink:href="../537/3114537.xml">
Pyoderma gangrenosum</link>&nbsp;·  <link xlink:type="simple" xlink:href="../845/2917845.xml">
Sacroiliitis</link>&nbsp;·  <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../053/1257053.xml">
Short bowel syndrome</link></disease>
&nbsp;·  <link xlink:type="simple" xlink:href="../424/324424.xml">
Small bowel obstruction</link>&nbsp;·  <link xlink:type="simple" xlink:href="../498/682498.xml">
Stenosis</link></col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";;" class="navbox-group">
History</col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<scientist wordnetid="110560637" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../699/564699.xml">
Giovanni Battista Morgagni</link></scientist>
&nbsp;·  <person wordnetid="100007846" confidence="0.9508927676800064">
<scientist wordnetid="110560637" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../472/3020472.xml">
Burrill Bernard Crohn</link></scientist>
</person>
</col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";;" class="navbox-group">
Organizations</col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<link xlink:type="simple" xlink:href="../059/9477059.xml">
Crohn's and Colitis Foundation of America</link>&nbsp;·  <link xlink:type="simple" xlink:href="../721/1490721.xml">
National Society for Colitis and Crohn's Disease</link></col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";;" class="navbox-group">
People</col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<link xlink:type="simple" xlink:href="../331/6187331.xml">
List of people diagnosed with Crohn's disease</link></col>
</row>
</table>
</col>
</row>
</table>
</p>

<p>

<table style=";" class="navbox" cellspacing="0">
<row>
<col style="padding:2px;">
<table style="width:100%;background:transparent;color:inherit;;" class="nowraplinks collapsible autocollapse " cellspacing="0">
<row>
<header colspan="2" style=";background:Silver" class="navbox-title">
<link xlink:type="simple" xlink:href="../423/165423.xml">
Digestive system</link> - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../956/1062956.xml">
Digestive disease</link></disease>
 - <link xlink:type="simple" xlink:href="../976/12976.xml">
Gastroenterology</link> (primarily , )</header>
</row>
<row style="height:2px;">

</row>
<row>
<col style=";background:#fd6;;" class="navbox-group">
<link>
Upper GI tract</link></col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<table style="width:100%;;;;" class="nowraplinks  navbox-subgroup" cellspacing="0">
<row>
<col style=";padding-left:0em;padding-right:0em;background-color: #fd6;" class="navbox-group">
<disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../250/17762250.xml">
Esophagus</link></disease>
</col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<link xlink:type="simple" xlink:href="../010/197010.xml">
Esophagitis</link> (<disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../305/5176305.xml">
Candidal</link></disease>
) - <it>rupture</it> (<disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../534/2597534.xml">
Boerhaave syndrome</link></disease>
, <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../536/1010536.xml">
Mallory-Weiss syndrome</link></disease>
) - <link xlink:type="simple" xlink:href="../126/9188126.xml">
UES</link> (<disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../233/920233.xml">
Zenker's diverticulum</link></disease>
) - <link xlink:type="simple" xlink:href="../802/196802.xml">
LES</link> (<link xlink:type="simple" xlink:href="../998/196998.xml">
Barrett's esophagus</link>) - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../950/196950.xml">
Esophageal motility disorder</link></disease>
 (<disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../198/6943198.xml">
Nutcracker esophagus</link></disease>
, <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../093/189093.xml">
Achalasia</link></disease>
, <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../252/6948252.xml">
Diffuse esophageal spasm</link></disease>
, <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../991/196991.xml">
GERD</link></disease>
) - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../792/8323792.xml">
Esophageal stricture</link></disease>
 - <link xlink:type="simple" xlink:href="../433/1304433.xml">
Megaesophagus</link></col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";padding-left:0em;padding-right:0em;background-color: #fd6;" class="navbox-group">
<disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../699/17615699.xml">
Stomach</link></disease>
</col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<link xlink:type="simple" xlink:href="../473/1002473.xml">
Gastritis</link> (<link xlink:type="simple" xlink:href="../873/1599873.xml">
Atrophic</link>, <link>
Ménétrier's disease</link>, <link xlink:type="simple" xlink:href="../123/869123.xml">
Gastroenteritis</link>) - <link xlink:type="simple" xlink:href="../791/63791.xml">
Peptic (gastric)&nbsp;ulcer</link> (<link xlink:type="simple" xlink:href="../594/1010594.xml">
Cushing ulcer</link>, <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../141/732141.xml">
Dieulafoy's lesion</link></disease>
) - <link xlink:type="simple" xlink:href="../986/1231986.xml">
Dyspepsia</link> - <link xlink:type="simple" xlink:href="../268/714268.xml">
Pyloric stenosis</link> - <link xlink:type="simple" xlink:href="../721/1002721.xml">
Achlorhydria</link> - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../133/12128133.xml">
Gastroparesis</link></disease>
 - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../280/747280.xml">
Gastroptosis</link></disease>
 - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../967/12759967.xml">
Portal hypertensive gastropathy</link></disease>
 - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../983/3725983.xml">
Gastric antral vascular ectasia</link></disease>
 - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../236/1389236.xml">
Gastric dumping syndrome</link></disease>
 - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../478/8690478.xml">
Gastric volvulus</link></disease>
</col>
</row>
</table>
</col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";background:#fd6;;" class="navbox-group">
<link xlink:type="simple" xlink:href="../343/61343.xml">
Intestinal</link>/
<link xlink:type="simple" xlink:href="../889/3452889.xml">
enteropathy</link></col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<table style="width:100%;;;;" class="nowraplinks  navbox-subgroup" cellspacing="0">
<row>
<col style=";padding-left:0em;padding-right:0em;background-color: #fd6;" class="navbox-group">
<link xlink:type="simple" xlink:href="../610/99610.xml">
Small intestine</link>/(<link xlink:type="simple" xlink:href="../184/70184.xml">
duodenum</link>/<link xlink:type="simple" xlink:href="../608/99608.xml">
jejunum</link>/<link xlink:type="simple" xlink:href="../599/99599.xml">
ileum</link>)</col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<link xlink:type="simple" xlink:href="../960/525960.xml">
Enteritis</link> (<disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../267/9664267.xml">
Duodenitis</link></disease>
, <link xlink:type="simple" xlink:href="../960/525960.xml">
Jejunitis</link>, <link xlink:type="simple" xlink:href="../949/513949.xml">
Ileitis</link>)<p>

<link xlink:type="simple" xlink:href="../791/63791.xml">
Peptic (duodenal)&nbsp;ulcer</link> (<disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../592/1010592.xml">
Curling's ulcer</link></disease>
)</p>
<p>

<link xlink:type="simple" xlink:href="../953/820953.xml">
Malabsorption</link>: <link xlink:type="simple" xlink:href="../526/63526.xml">
Coeliac</link> - <link xlink:type="simple" xlink:href="../464/1231464.xml">
Tropical sprue</link> - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../445/3640445.xml">
Blind loop syndrome</link></disease>
 - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../943/544943.xml">
Whipple's</link></disease>
 - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../053/1257053.xml">
Short bowel syndrome</link></disease>
 - <link xlink:type="simple" xlink:href="../337/1024337.xml">
Steatorrhea</link></p>
</col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";padding-left:0em;padding-right:0em;background-color: #fd6;" class="navbox-group">
<link xlink:type="simple" xlink:href="../366/59366.xml">
Large intestine</link>(<link xlink:type="simple" xlink:href="../611/99611.xml">
appendix</link>/<anatomy wordnetid="106057539" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../365/59365.xml">
colon</link></anatomy>
)</col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<link xlink:type="simple" xlink:href="../980/70980.xml">
Appendicitis</link> - <link xlink:type="simple" xlink:href="../308/1072308.xml">
Colitis</link> (<condition wordnetid="113920835" confidence="0.8">
<state wordnetid="100024720" confidence="0.8">
<link xlink:type="simple" xlink:href="../047/147047.xml">
Pseudomembranous</link></state>
</condition>
, <link xlink:type="simple" xlink:href="../531/63531.xml">
Ulcerative</link>, <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../176/4429176.xml">
Ischemic</link></disease>
, <link xlink:type="simple" xlink:href="../847/2970847.xml">
Microscopic</link>, <link xlink:type="simple" xlink:href="../724/3850724.xml">
Collagenous</link>, <link xlink:type="simple" xlink:href="../447/7386447.xml">
Lymphocytic</link>)<p>

<disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../609/881609.xml">
Functional colonic disease</link></disease>
 (<link xlink:type="simple" xlink:href="../596/210596.xml">
IBS</link>, <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../155/4101155.xml">
Intestinal pseudoobstruction</link></disease>
/<disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../992/4100992.xml">
Ogilvie syndrome</link></disease>
)</p>
<p>

<link xlink:type="simple" xlink:href="../330/2593330.xml">
Megacolon</link>/<disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../980/1284980.xml">
Toxic megacolon</link></disease>
 - <link xlink:type="simple" xlink:href="../041/725041.xml">
Diverticulitis</link>/<link xlink:type="simple" xlink:href="../082/725082.xml">
Diverticulosis</link></p>
</col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";padding-left:0em;padding-right:0em;background-color: #fd6;" class="navbox-group">
Large and/or small</col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../613/3119613.xml">
Enterocolitis</link></disease>
 (<link xlink:type="simple" xlink:href="../811/2183811.xml">
Necrotizing</link>) - <link xlink:type="simple" xlink:href="../967/616967.xml">
IBD</link>&nbsp;(<link xlink:type="simple" xlink:href="../522/63522.xml">
Crohn's disease</link>)<p>

<it><link xlink:type="simple" xlink:href="../872/5200872.xml">
vascular</link></it>: <link>
Abdominal&nbsp;angina</link> - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../690/11122690.xml">
Mesenteric ischemia</link></disease>
 - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../676/699676.xml">
Angiodysplasia</link></disease>
</p>
<p>

<happening wordnetid="107283608" confidence="0.8">
<event wordnetid="100029378" confidence="0.8">
<emergency wordnetid="107417405" confidence="0.8">
<crisis wordnetid="107417644" confidence="0.8">
<psychological_feature wordnetid="100023100" confidence="0.8">
<juncture wordnetid="107416714" confidence="0.8">
<link xlink:type="simple" xlink:href="../424/324424.xml">
Bowel obstruction</link></juncture>
</psychological_feature>
</crisis>
</emergency>
</event>
</happening>
: <link xlink:type="simple" xlink:href="../785/1078785.xml">
Ileus</link> - <link>
Intussusception</link> - <link xlink:type="simple" xlink:href="../455/1604455.xml">
Volvulus</link> - <link xlink:type="simple" xlink:href="../040/1606040.xml">
Fecal impaction</link></p>
<p>

<link xlink:type="simple" xlink:href="../509/168509.xml">
Constipation</link> - <link xlink:type="simple" xlink:href="../951/53951.xml">
Diarrhea</link></p>
</col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";padding-left:0em;padding-right:0em;background-color: #fd6;" class="navbox-group">
<link xlink:type="simple" xlink:href="../671/19385671.xml">
Rectum</link>/<link xlink:type="simple" xlink:href="../ury/25th_century.xml">
anus</link></col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<link xlink:type="simple" xlink:href="../913/2161913.xml">
Proctitis</link> (<disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../424/3381424.xml">
Radiation proctitis</link></disease>
) - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../376/3983376.xml">
Proctalgia fugax</link></disease>
 - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../040/657040.xml">
Rectal prolapse</link></disease>
 - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../657/490657.xml">
Anal fissure</link></disease>
/<link xlink:type="simple" xlink:href="../909/3591909.xml">
Anal fistula</link> - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../885/1560885.xml">
Anal abscess</link></disease>
</col>
</row>
</table>
</col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";background:#fd6;;" class="navbox-group">
<link xlink:type="simple" xlink:href="../773/18268773.xml">
Accessory</link></col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<table style="width:100%;;;;" class="nowraplinks  navbox-subgroup" cellspacing="0">
<row>
<col style=";padding-left:0em;padding-right:0em;background-color: #fd6;" class="navbox-group">
<link xlink:type="simple" xlink:href="../271/865271.xml">
Liver</link></col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<link xlink:type="simple" xlink:href="../238/38238.xml">
Hepatitis</link> (<link xlink:type="simple" xlink:href="../070/607070.xml">
Viral hepatitis</link>, <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../869/660869.xml">
Autoimmune hepatitis</link></disease>
, <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../078/644078.xml">
Alcoholic hepatitis</link></disease>
) - <link xlink:type="simple" xlink:href="../060/37060.xml">
Cirrhosis</link> (<disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../339/697339.xml">
PBC</link></disease>
) - <link xlink:type="simple" xlink:href="../521/945521.xml">
Fatty liver</link> (<link xlink:type="simple" xlink:href="../906/6319906.xml">
NASH</link>) - <it><link xlink:type="simple" xlink:href="../872/5200872.xml">
vascular</link></it> (<disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../185/14902185.xml">
Hepatic veno-occlusive disease</link></disease>
, <link xlink:type="simple" xlink:href="../615/707615.xml">
Portal hypertension</link>, <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../793/6856793.xml">
Nutmeg liver</link></disease>
) - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../039/307039.xml">
Alcoholic liver disease</link></disease>
 - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../831/9807831.xml">
Liver failure</link></disease>
 (<link xlink:type="simple" xlink:href="../043/1105043.xml">
Hepatic encephalopathy</link>, <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../250/1226250.xml">
Acute liver failure</link></disease>
) - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../882/10529882.xml">
Liver abscess</link></disease>
 - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../330/2204330.xml">
Hepatorenal syndrome</link></disease>
 - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../972/10731972.xml">
Peliosis hepatis</link></disease>
</col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";padding-left:0em;padding-right:0em;background-color: #fd6;" class="navbox-group">
<link xlink:type="simple" xlink:href="../020/197020.xml">
Gallbladder</link></col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<link xlink:type="simple" xlink:href="../387/305387.xml">
Cholecystitis</link> - <link xlink:type="simple" xlink:href="../531/287531.xml">
Gallstone</link>s/<link xlink:type="simple" xlink:href="../531/287531.xml">
Cholecystolithiasis</link> - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../509/12673509.xml">
Cholesterolosis</link></disease>
 - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../377/8452377.xml">
Rokitansky-Aschoff sinuses</link></disease>
 - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../307/6038307.xml">
Postcholecystectomy syndrome</link></disease>
</col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";padding-left:0em;padding-right:0em;background-color: #fd6;" class="navbox-group">
<link xlink:type="simple" xlink:href="../021/197021.xml">
Bile duct</link>/other <link xlink:type="simple" xlink:href="../496/594496.xml">
biliary tree</link></col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<link xlink:type="simple" xlink:href="../707/6673707.xml">
Cholangitis</link> (<link xlink:type="simple" xlink:href="../489/864489.xml">
PSC</link>, <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../827/5544827.xml">
Ascending</link></disease>
) - <link xlink:type="simple" xlink:href="../843/2632843.xml">
Cholestasis</link>/<disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../886/885886.xml">
Mirizzi's syndrome</link></disease>
 - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../213/5059213.xml">
Biliary fistula</link></disease>
 - <link xlink:type="simple" xlink:href="../132/10424132.xml">
Haemobilia</link> - <link xlink:type="simple" xlink:href="../531/287531.xml">
Gallstone</link>s/<link xlink:type="simple" xlink:href="../531/287531.xml">
Cholelithiasis</link><it><link xlink:type="simple" xlink:href="../918/760918.xml">
common bile duct</link></it> (<link xlink:type="simple" xlink:href="../416/1285416.xml">
Choledocholithiasis</link>, <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../835/18292835.xml">
Biliary dyskinesia</link></disease>
)</col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";padding-left:0em;padding-right:0em;background-color: #fd6;" class="navbox-group">
<disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../147/5323147.xml">
Pancreatic</link></disease>
</col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<link xlink:type="simple" xlink:href="../547/63547.xml">
Pancreatitis</link> (<disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../086/1035086.xml">
Acute</link></disease>
, <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../125/1035125.xml">
Chronic</link></disease>
, <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../461/5565461.xml">
Hereditary</link></disease>
) - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../995/2565995.xml">
Pancreatic pseudocyst</link></disease>
 - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../371/3952371.xml">
Exocrine pancreatic insufficiency</link></disease>
 - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../466/2755466.xml">
Pancreatic fistula</link></disease>
</col>
</row>
</table>
</col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";background:#fd6;;" class="navbox-group">
<link xlink:type="simple" xlink:href="../347/76347.xml">
Hernia</link></col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<link xlink:type="simple" xlink:href="../076/3630076.xml">
Diaphragmatic</link>: <link xlink:type="simple" xlink:href="../920/1966920.xml">
Congenital diaphragmatic</link> - <link xlink:type="simple" xlink:href="../188/198188.xml">
Hiatus</link><p>

<link>
Abdominal hernia</link>: <link xlink:type="simple" xlink:href="../992/898992.xml">
Inguinal</link> (<link xlink:type="simple" xlink:href="../500/956500.xml">
Indirect</link>, <link xlink:type="simple" xlink:href="../513/956513.xml">
Direct</link>) -  <link xlink:type="simple" xlink:href="../602/3080602.xml">
Umbilical</link> - <link xlink:type="simple" xlink:href="../655/4606655.xml">
Incisional</link> - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../483/4606483.xml">
Femoral</link></disease>
</p>
<p>

<disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../112/14763112.xml">
Obturator hernia</link></disease>
 - <link xlink:type="simple" xlink:href="../204/4604204.xml">
Spigelian hernia</link></p>
</col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";background:#fd6;;" class="navbox-group">
<link xlink:type="simple" xlink:href="../583/40583.xml">
Peritoneal</link></col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<link xlink:type="simple" xlink:href="../549/142549.xml">
Peritonitis</link> (<link xlink:type="simple" xlink:href="../465/986465.xml">
Spontaneous bacterial peritonitis</link>) - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../146/6546146.xml">
Hemoperitoneum</link></disease>
 - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../746/3299746.xml">
Pneumoperitoneum</link></disease>
</col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";background:#fd6;;" class="navbox-group">
<disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../585/904585.xml">
GI bleeding</link></disease>
</col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../100/540100.xml">
Upper</link></disease>
 (<link xlink:type="simple" xlink:href="../173/540173.xml">
Hematemesis</link>, <link xlink:type="simple" xlink:href="../176/540176.xml">
Melena</link>) - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../249/3355249.xml">
Lower</link></disease>
 (<link xlink:type="simple" xlink:href="../073/540073.xml">
Hematochezia</link>)</col>
</row>
<row style="height:2px">

</row>
<row>
<col colspan="2" style="width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<it>See also , ''</it></col>
</row>
</table>
</col>
</row>
</table>
</p>



</sec>
</bdy>
</entity>
</article>
